Religion and Ethics Forum
General Category => Politics & Current Affairs => Topic started by: Nearly Sane on September 22, 2015, 07:12:11 PM
-
The giants trying to lead the USA talk pish on vaccines.
http://mobile.nytimes.com/2015/09/18/upshot/not-up-for-debate-the-science-behind-vaccination.html?referrer=
-
If this were an intellectual limbo competition, we might be watching the attempt at the nanoPalin.
http://www.haaretz.com/opinion/.premium-1.677122
-
The look make Farage look like a sensible bloke.
-
And these cretins want to become Commander in Chief of all US armed forces?
It's bad enough in this country where many people seem to believe that the Daily Mail is better informed on matters clinical than their own GP ....
Did anyone hear the news story about a drug developed GSK and costing about a dollar a pill being sold to some other company which plans to sell the same drug for about $700 a pill?
Only in America ....
-
And these cretins want to become Commander in Chief of all US armed forces?
It's bad enough in this country where many people seem to believe that the Daily Mail is better informed on matters clinical than their own GP ....
Did anyone hear the news story about a drug developed GSK and costing about a dollar a pill being sold to some other company which plans to sell the same drug for about $700 a pill?
Only in America ....
Not "plans to" - has confirmed it!
From Yahoo!
A pharmaceutical start-up owner is facing criticism for raising the price of a drug used to treat life-threatening infections, like AIDS, from £9 to £484 per pill. Martin Shkreli, 32, of New York start-up, Turing Pharmaceuticals, bought the rights to the drug Daraprim, also known as pyrimethamine, before hiking its price by nearly 5,000%.
Daraprim is a 62-year-old drug used for the treatment of infections, like malaria, toxoplasmosis and HIV.
Shkreli has received heavy criticism from specialists in infectious disease, including a letter from the Infectious Diseases Society of America (IDSA) and the HIV Medicine Association.
"Please help us improve public health by immediately implementing a rational and fair pricing strategy for pyrimethamine that keeps treatment for a potentially fatal condition accessible to our patients," read the letter, reported The Independent.
-
On the subject of Daraprim
http://www.nytimes.com/1999/02/23/us/gertrude-elion-drug-developer-dies-at-81.html
-
If the drug has been around for 62 years then surely it no longer has patent protection and can be produced as a generic - possibly by some company in India.
-
http://www.nytimes.com/2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html?_r=0
It's possible, with the higher price, that generic versions become economic, despite obstacles attempting to thwart other potentisl producers.